Ligand Pharma (LGND) Posts Q3 Loss of 3c, Tops by 1c; Guides
More News related to LGND
- Ligand Pharma (LGND) Reports Data on SARM
- Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Gerontological Society of America Annual Meeting
- Ligand Pharma (LGND) Receives $2M in Milestone Payments from N.V. Organon
- Ligand Earns $2 Million in Milestone Payments from Merck & Co., Inc.
- Morning Movers 11/06: ACLS, CVM, ZIOP, LPSN, CABL, ZGEN Higher; NHWK, GOK, CROX, CVI, RAIL, CSTR Lower
More News related to Earnings
- Trading Radar for 11/24: Heinz (HNZ), Dollar Tree (DLTR), Eaton Vance (EV), Hormel Foods (HRL), J. Crew (JCG) Report
- Afternoon ETF Check: GDX, KBE Higher; UUP Lower
- Unusual 11 Mid-Day Movers 11/23: ABIO, SEED, FNET, CDTI Higher; NYNY, GGR, TTIL, PEET Lower
- Best of the Web 11/23: Suicides On the Rise, U.S. Debt Service Could Top $700B, Really? An Insider Trading Beauty Queen
- Notable Analyst Rating Changes 11/23: SBUX, DE, SEED, NDAQ Upgraded; AGU, TRA, CIEN, FL Downgraded
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reports Q3 loss of $0.03, 1 cents better than the analyst estimate of ($0.04). Revenue for the quarter was $7.9 million, which compares to the estimate of $7.08 million.
Sees FY09 sales $33 - $34 million, versus $34.30 million consensus.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.09Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
